

TS, DARKZONE, GC\_TONSIL\_BCELL\_DN, GSE12845\_IJD\_POS\_BLOOD\_VS, DARKZONE, GC\_TONSIL\_BCELL\_DN, GSE17974\_0H\_VS\_48H\_IN\_VITRO, ACT\_CD4\_TCELL\_DN, GSE17974\_0H\_VS\_48H\_IN\_VITRO, ACT\_CD4\_TCELL\_DN, GSE17974\_CTRL\_VS\_ACT\_IL4\_AND\_ANTIL112\_2H\_CD4\_TCELL\_DN, GSE17974\_CTRL\_VS\_ACT\_IL4\_AND\_ANTIL112\_2H\_CD4\_TCELL\_DN, GSE12845\_IJD\_NBC\_BLOOD\_VS, DARKZONE, GC\_TONSIL\_BCELL\_DN, GSE12845\_IJD\_NBC\_BLOOD\_VS, DARKZONE, GC\_TONSIL\_BCELL\_DN, GSE12845\_IJD\_POS\_BLOOD\_VS, DARKZONE, GC\_TONSIL\_BCELL\_DN, GSE1330\_WT\_VS\_IKAROS\_KO, MEGAKARYOCYTE\_ERYTHROID\_PROGENITOR\_UP, GSE1330\_WT\_VS\_IKAROS\_KO, MEGAKARYOCYTE\_ERYTHROID\_PROGENITOR\_UP, GSE12392\_WT\_VS\_IJNB\_KO, CD8A, NEG\_SPLEEN\_DC\_UP, GSE12392\_WT\_VS\_IJNB\_KO, CD8A, NEG\_SPLEEN\_DC\_UP, GSE2962\_MAST\_CELL\_VS\_EPF\_MEMORY\_CD4\_TCELL\_UP, GSE2962\_MAST\_CELL\_VS\_EPF\_MEMORY\_CD4\_TCELL\_UP, GSE39152\_BRAIN\_VS\_SPLEEN\_CD103\_NEG\_MEMORY\_CD8\_TCELL\_UP, GSE39152\_BRAIN\_VS\_SPLEEN\_CD103\_NEG\_MEMORY\_CD8\_TCELL\_UP, GSE15735\_CTRL\_VS\_HDAC\_INHIBITOR\_TREATED\_CD4\_TCELL\_2H\_UP, GSE15735\_CTRL\_VS\_HDAC\_INHIBITOR\_TREATED\_CD4\_TCELL\_2H\_UP, GSE17721\_0.5H\_VS\_12H\_POLYVIC\_BMDC\_UP, GSE17721\_0.5H\_VS\_12H\_POLYVIC\_BMDC\_UP, GSE411\_WT\_VS\_SCKS3X\_TULARENSIS\_LVS\_NEUTROPHIL\_DN, GSE411\_WT\_VS\_SCKS3X\_TULARENSIS\_LVS\_NEUTROPHIL\_DN, GSE37416\_CTRL\_VS\_4H1\_F\_TULARENSIS\_LVS\_NEUTROPHIL\_DN, GSE37416\_CTRL\_VS\_4H1\_F\_TULARENSIS\_LVS\_NEUTROPHIL\_DN, GSE29618\_PRE\_VS\_DAY7\_POST\_TTV\_FLU\_VACCINE\_MONOCYTE\_DN, GSE29618\_PRE\_VS\_DAY7\_POST\_TTV\_FLU\_VACCINE\_MONOCYTE\_DN, MIR6128, MIR6128, MIR6715A\_3P, MIR6715A\_3P, GSE906\_HEALTHY\_VS\_TYPE\_1\_DIABETES\_PBMC\_4MONTH\_POST\_DX\_DN, GSE906\_HEALTHY\_VS\_TYPE\_1\_DIABETES\_PBMC\_4MONTH\_POST\_DX\_DN, HP\_ECLABION, HP\_ECLABION, GSE17721\_LPS\_VS\_GARDIQUIMOD\_8H\_BMDC\_UP, GSE17721\_LPS\_VS\_GARDIQUIMOD\_8H\_BMDC\_UP, MIR8298, MIR8298, CORP\_POSITIVE\_REGULATION\_OF\_VIRAL\_PROCESS, CORP\_POSITIVE\_REGULATION\_OF\_VIRAL\_PROCESS, GSE17721\_12H\_VS\_24H\_CPG\_BMDC\_UP, GSE17721\_12H\_VS\_24H\_CPG\_BMDC\_UP, GSE4955\_10H\_VS\_30H\_ACT\_CD4\_TCELL\_UP, GSE4955\_10H\_VS\_30H\_ACT\_CD4\_TCELL\_UP, GSE20366\_CD103\_POS\_VS\_CD103\_KLRG1\_UP, GSE20366\_CD103\_POS\_VS\_CD103\_KLRG1\_UP, TREG\_UP, GSE20366\_CD103\_POS\_VS\_CD103\_KLRG1\_UP, TREG\_UP, IWANAGA, CARCINOGENESIS\_BY\_KRAS\_UP, IWANAGA, CARCINOGENESIS\_BY\_KRAS\_UP, MODULE\_332, MODULE\_332, GSE906\_HEALTHY\_VS\_TYPE\_2\_DIABETES\_PBMC\_AT\_DX\_DN, GSE906\_HEALTHY\_VS\_TYPE\_2\_DIABETES\_PBMC\_AT\_DX\_DN, GSE37534\_GW1929\_VS\_ROSGLITAZONE\_TREATED\_CD4\_TCELL\_PPARG1\_FOXP3\_TRANSDUCED\_UP, GSE37534\_GW1929\_VS\_ROSGLITAZONE\_TREATED\_CD4\_TCELL\_PPARG1\_FOXP3\_TRANSDUCED\_UP, ACAGGGT\_MIR810A\_MIR810B, ACAGGGT\_MIR810A\_MIR810B, GSE11961\_FOLLICULAR\_BCELL\_VS\_PLASMA\_CELL\_DAY7\_UP, GSE11961\_FOLLICULAR\_BCELL\_VS\_PLASMA\_CELL\_DAY7\_UP, RAX2\_TARGET\_GENES\_RAX2\_TARGET\_GENES, RAX2\_TARGET\_GENES\_RAX2\_TARGET\_GENES, HP\_CHRONIC\_OTITIS\_MEDIA, HP\_CHRONIC\_OTITIS\_MEDIA, GSE22886\_IIGA\_VS\_IJGM\_MEMORY\_BCELL\_UP, GSE22886\_IIGA\_VS\_IJGM\_MEMORY\_BCELL\_UP, CORP\_LYMPHOCTE\_ACTIVATION\_INVOLVED\_IN\_IMMUNE\_RESPONSE, CORP\_LYMPHOCTE\_ACTIVATION\_INVOLVED\_IN\_IMMUNE\_RESPONSE, IJAZAG\_TGFB1\_SIGNALING\_VIA\_SMAAD1\_UP, IJAZAG\_TGFB1\_SIGNALING\_VIA\_SMAAD1\_UP, HP\_ADDUCTED\_THUMB, HP\_ADDUCTED\_THUMB, MIR6736\_3P, MIR6736\_3P, GSE17721\_CPG\_VS\_GARDIQUIMOD\_2H\_BMDC\_UP, GSE17721\_CPG\_VS\_GARDIQUIMOD\_2H\_BMDC\_UP, GSE16882\_MONOCYTE\_VS\_MACROPHAGE\_UP, GSE16882\_MONOCYTE\_VS\_MACROPHAGE\_UP, GSE17721\_CPG\_VS\_GARDIQUIMOD\_16H\_BMDC\_UP, GSE17721\_CPG\_VS\_GARDIQUIMOD\_16H\_BMDC\_UP, GGTGAAG\_MIR812\_GGTGAAG\_MIR812, GGTGAAG\_MIR812\_GGTGAAG\_MIR812, MODULE\_145, MODULE\_145, HP\_FAILURE\_TO\_THRIVE\_IN\_INFANCY, HP\_FAILURE\_TO\_THRIVE\_IN\_INFANCY, HP\_ECTOPIC\_KIDNEY, HP\_ECTOPIC\_KIDNEY, GSE21927\_SPLEEN\_VS\_TUMOR\_MONOCYTE\_C57BL6\_DN, GSE21927\_SPLEEN\_VS\_TUMOR\_MONOCYTE\_C57BL6\_DN, GSE12707\_ATH1L1\_HYPMOMORPH\_VS\_WT\_THYMUS\_UP, GSE12707\_ATH1L1\_HYPMOMORPH\_VS\_WT\_THYMUS\_UP, HP\_INCREASED\_BONE\_MINERAL\_DENSITY, HP\_INCREASED\_BONE\_MINERAL\_DENSITY, KLEIN\_PRIMARY\_EFFUSION\_LYMPHOMA\_DN, KLEIN\_PRIMARY\_EFFUSION\_LYMPHOMA\_DN, MIR4691\_3P, MIR4691\_3P, BCAT\_BILD\_ET.AL\_DN, BCAT\_BILD\_ET.AL\_DN, BRACHAT\_RESPONSE\_TO\_CAMPOTHECIN\_DN, BRACHAT\_RESPONSE\_TO\_CAMPOTHECIN\_DN, HP\_ABNORMAL\_CIRCULATING\_IJG\_LEVEL, HP\_ABNORMAL\_CIRCULATING\_IJG\_LEVEL, BROWNE\_HCMV\_INFECTION\_10HR\_DN, BROWNE\_HCMV\_INFECTION\_10HR\_DN, GOME\_CYSSTEINE\_TYPE\_ENDOPEPTIDASE\_ACTIVITY, GOME\_CYSSTEINE\_TYPE\_ENDOPEPTIDASE\_ACTIVITY, HP\_SKIN\_DM1P6, HP\_SKIN\_DM1P6, HP\_ABNORMAL\_THROMBOSIS, HP\_ABNORMAL\_THROMBOSIS, HP\_ABNORMALITY\_OF\_THE\_PULMONARY\_ARTERY, HP\_ABNORMALITY\_OF\_THE\_PULMONARY\_ARTERY, MIR649, MIR649, HP\_POSTERIOR\_EMBRYOTOXON, HP\_POSTERIOR\_EMBRYOTOXON, HP\_PULMONARY\_ARTERY\_STENOSIS, HP\_PULMONARY\_ARTERY\_STENOSIS, GSE22796\_BCELL\_VS\_NEUTROPHIL\_DN, GSE22796\_BCELL\_VS\_NEUTROPHIL\_DN, KEGG\_TIGHT\_JUNCTION, KEGG\_TIGHT\_JUNCTION, WP\_MITOCHONDRIAL\_GENE\_EXPRESSION, WP\_MITOCHONDRIAL\_GENE\_EXPRESSION, HP\_ABNORMAL\_B\_CELL\_MORPHOLOGY, HP\_ABNORMAL\_B\_CELL\_MORPHOLOGY, HP\_MYOCARDIAL\_INFARCTION, HP\_MYOCARDIAL\_INFARCTION, MIR8704, MIR8704, GOLUB\_ALL\_VS\_AML\_UP, GOLUB\_ALL\_VS\_AML\_UP, HP\_PATELLAR\_DISLOCATION, HP\_PATELLAR\_DISLOCATION, NUTT\_GBM\_VS\_AD\_GLIOMA\_UP, NUTT\_GBM\_VS\_AD\_GLIOMA\_UP, CORP\_NEGATIVE\_REGULATION\_OF\_CELL\_CELL\_ADHESION, CORP\_NEGATIVE\_REGULATION\_OF\_CELL\_CELL\_ADHESION, REACTOME\_SIGNALING\_BY\_SCF\_KIT, REACTOME\_SIGNALING\_BY\_SCF\_KIT, HP\_CHOLELITHIASIS, HP\_CHOLELITHIASIS, FAET\_B\_CELL\_WITH\_VHL\_REARRANGEMENTS\_UP, FAET\_B\_CELL\_WITH\_VHL\_REARRANGEMENTS\_UP, GOME\_AMINOPEPTIDASE\_ACTIVITY, GOME\_AMINOPEPTIDASE\_ACTIVITY, GSE46606\_IRF4HIGH\_VS\_IRF4MID\_CD40L\_IL2\_IL5\_DAY1\_STIMULATED\_BCELL\_DN, GSE46606\_IRF4HIGH\_VS\_IRF4MID\_CD40L\_IL2\_IL5\_DAY1\_STIMULATED\_BCELL\_DN, BOHN\_PRIMARY\_IMMUNODEFICIENCY\_SYNDROM\_DN, BOHN\_PRIMARY\_IMMUNODEFICIENCY\_SYNDROM\_DN, HP\_ABNORMALITY\_OF\_THE\_GASTRIC\_MUCOSA, HP\_ABNORMALITY\_OF\_THE\_GASTRIC\_MUCOSA, HP\_NEPHROLITHIASIS, HP\_NEPHROLITHIASIS, CORP\_LEUKOCYTE\_HOMEOSTASIS, CORP\_LEUKOCYTE\_HOMEOSTASIS, MARSON\_FOXP3\_TARGETS\_UP, MARSON\_FOXP3\_TARGETS\_UP, HP\_DECREASED\_CIRCULATING\_IJG\_LEVEL, HP\_DECREASED\_CIRCULATING\_IJG\_LEVEL, LI\_PBMC\_MENOMUNE\_A\_C\_Y\_W\_135\_AGE\_450\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_3DY\_NEGATIVE, LI\_PBMC\_MENOMUNE\_A\_C\_Y\_W\_135\_AGE\_450\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_3DY\_NEGATIVE, MIR3614\_5P, MIR3614\_5P, HP\_TONGUE\_FASCICULATIONS, HP\_TONGUE\_FASCICULATIONS, JIANG\_TIP30\_TARGETS\_UP, JIANG\_TIP30\_TARGETS\_UP, HP\_PULMONARY\_INFILTRATES, HP\_PULMONARY\_INFILTRATES, HP\_ABNORMAL\_RETINAL\_ARTERY\_MORPHOLOGY, HP\_ABNORMAL\_RETINAL\_ARTERY\_MORPHOLOGY, LINDSTEDT\_DENDRITIC\_CELL\_MATURATION\_C, LINDSTEDT\_DENDRITIC\_CELL\_MATURATION\_C, HP\_RETINAL\_VASCULAR\_TORTUOSITY, HP\_RETINAL\_VASCULAR\_TORTUOSITY, PARK\_TRETINON\_RESPONSE\_AND\_PML\_RARA\_FUSION, PARK\_TRETINON\_RESPONSE\_AND\_PML\_RARA\_FUSION, REACTOME\_APOPTOTIC\_CLEAVAGE\_OF\_CELLULAR\_PROTEINS, REACTOME\_APOPTOTIC\_CLEAVAGE\_OF\_CELLULAR\_PROTEINS, CORP\_IMMUNOGLOBULIN\_PRODUCTION\_INVOLVED\_IN\_IMMUNOGLOBULIN\_MEDIATED\_IMMUNE\_RESPONSE, CORP\_IMMUNOGLOBULIN\_PRODUCTION\_INVOLVED\_IN\_IMMUNOGLOBULIN\_MEDIATED\_IMMUNE\_RESPONSE, KENNY\_CTNNB1\_TARGETS\_DN, KENNY\_CTNNB1\_TARGETS\_DN, MIR6418\_5P, MIR6418\_5P, HP\_MEGALOCORNEA, HP\_MEGALOCORNEA, HP\_ABNORMAL\_CARTILAGE\_MORPHOLOGY, HP\_ABNORMAL\_CARTILAGE\_MORPHOLOGY, MIR2276\_5P, MIR2276\_5P, CORP\_PROTEIN\_DESTABILIZATION, CORP\_PROTEIN\_DESTABILIZATION, GOME\_CARBN\_CARBN\_LYASE\_ACTIVITY, GOME\_CARBN\_CARBN\_LYASE\_ACTIVITY, HP\_CAPILLARY\_MALFORMATION, HP\_CAPILLARY\_MALFORMATION, NIKOLSKY\_BREAST\_CANCER\_16P13\_AMPICON, NIKOLSKY\_BREAST\_CANCER\_16P13\_AMPICON, VANDESILUS\_COMMD1\_TARGETS\_GROUP\_3\_UP, VANDESILUS\_COMMD1\_TARGETS\_GROUP\_3\_UP, HP\_ABNORMALITY\_OF\_BLADDER\_MORPHOLOGY, HP\_ABNORMALITY\_OF\_BLADDER\_MORPHOLOGY, HP\_PULMONARY\_FIBROSIS, HP\_PULMONARY\_FIBROSIS, GOCC\_TRANS\_GOLGI\_NETWORK\_TRANSPORT\_VESICLE\_MEMBRANE, GOCC\_TRANS\_GOLGI\_NETWORK\_TRANSPORT\_VESICLE\_MEMBRANE, CORP\_PLATELET\_AGGREGATION, CORP\_PLATELET\_AGGREGATION, HP\_ABNORMAL\_PULMONARY\_THORACIC\_IMAGING\_FINDING, HP\_ABNORMAL\_PULMONARY\_THORACIC\_IMAGING\_FINDING, CTAGGCA\_MIR819, CTAGGCA\_MIR819, HP\_ABNORMAL\_CIRCULATING\_IJG\_LEVEL, HP\_ABNORMAL\_CIRCULATING\_IJG\_LEVEL, MALONEY\_RESPONSE\_TO\_17AAG\_UP, MALONEY\_RESPONSE\_TO\_17AAG\_UP, CORP\_HOMOTYPIC\_CELL\_CELL\_ADHESION, CORP\_HOMOTYPIC\_CELL\_CELL\_ADHESION, HP\_HYPOCONADOTROPIC\_HYPOCONADISM, HP\_HYPOCONADOTROPIC\_HYPOCONADISM, BIOCARTA\_TPO\_PATHWAY, BIOCARTA\_TPO\_PATHWAY, MIR1272, MIR1272, PID\_SYNDICAN\_2\_PATHWAY, PID\_SYNDICAN\_2\_PATHWAY, IVANOVA\_HEMATOPOIESIS\_STEM\_CELL\_SHORT\_TERM, IVANOVA\_HEMATOPOIESIS\_STEM\_CELL\_SHORT\_TERM, BURTON\_ADIPOGENESIS\_PEAK\_AT\_8HR, BURTON\_ADIPOGENESIS\_PEAK\_AT\_8HR, HP\_ABNORMAL\_VITAMIN\_B12\_LEVEL, HP\_ABNORMAL\_VITAMIN\_B12\_LEVEL, CHEN\_PDGFR\_TARGETS, CHEN\_PDGFR\_TARGETS, GOCC\_BW1\_TYPE\_COMPLEX, GOCC\_BW1\_TYPE\_COMPLEX, BRACHAT\_RESPONSE\_TO\_METHOTREXATE\_DN, BRACHAT\_RESPONSE\_TO\_METHOTREXATE\_DN, HP\_HYPOPLASIA\_OF\_THE\_ZYGOMATIC\_BONE, HP\_HYPOPLASIA\_OF\_THE\_ZYGOMATIC\_BONE, HP\_BRONCHITIS, HP\_BRONCHITIS, MODULE\_419, MODULE\_419, HP\_DECREASED\_CIRCULATING\_TOTAL\_IJGM, HP\_DECREASED\_CIRCULATING\_TOTAL\_IJGM, CORP\_DEVELOPMENT\_OF\_PRIMARY\_FEMALE\_SEXUAL\_CHARACTERISTICS, CORP\_DEVELOPMENT\_OF\_PRIMARY\_FEMALE\_SEXUAL\_CHARACTERISTICS, HP\_SOUND\_SENSITIVITY, HP\_SOUND\_SENSITIVITY, NICK\_RESPONSE\_TO\_PROCT\_TREATMENT\_DN, NICK\_RESPONSE\_TO\_PROCT\_TREATMENT\_DN, HP\_RECTAL\_PROLAPSE, HP\_RECTAL\_PROLAPSE, HP\_HIGH\_HYPERMETROPIA, HP\_HIGH\_HYPERMETROPIA, GOCC\_ENDOSOME\_LUMEN, GOCC\_ENDOSOME\_LUMEN, MIR309\_3P, MIR309\_3P, CORP\_NEGATIVE\_REGULATION\_OF\_CELL\_AGING, CORP\_NEGATIVE\_REGULATION\_OF\_CELL\_AGING, HP\_INSOMNIA, HP\_INSOMNIA, CORP\_REGULATION\_OF\_MRNA\_POLYADENYLATION, CORP\_REGULATION\_OF\_MRNA\_POLYADENYLATION, CORP\_GLYCOLYTIC\_PROCESS\_THROUGH\_FRUCTOSE\_6\_PHOSPHATE, CORP\_GLYCOLYTIC\_PROCESS\_THROUGH\_FRUCTOSE\_6\_PHOSPHATE, REACTOME\_RHO\_GTPASE\_ACTIVATION\_NADPH\_OXIDASES, REACTOME\_RHO\_GTP